These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12907021)

  • 1. New generation versus conventional antipsychotics.
    Geddes J; Harrison P; Freemantle N
    Lancet; 2003 Aug; 362(9381):404; author reply 404-5. PubMed ID: 12907021
    [No Abstract]   [Full Text] [Related]  

  • 2. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 3. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 4. A meta-analysis of the efficacy of second-generation antipsychotics.
    Davis JM; Chen N; Glick ID
    Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of antipsychotic dose reduction.
    Uchida H; Suzuki T; Takeuchi H; Mamo DC
    Am J Psychiatry; 2010 Aug; 167(8):994; author reply 994-5. PubMed ID: 20693469
    [No Abstract]   [Full Text] [Related]  

  • 6. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.
    Stensland MD; Ascher-Svanum H; Lawson AH; Conley RR
    J Clin Psychiatry; 2009 Aug; 70(8):1189-90; author reply 1190-91. PubMed ID: 19758530
    [No Abstract]   [Full Text] [Related]  

  • 8. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 9. Are new drugs for schizophrenia better than old ones?
    Gøtzsche P
    Lancet; 2009 Apr; 373(9671):1248; author reply 1249-50. PubMed ID: 19362667
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia.
    Jaffe AB; Levine J
    J Clin Psychiatry; 2003; 64 Suppl 17():3-6. PubMed ID: 14680419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].
    Gazdag G; Tolna J; Bitter I
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):189-95. PubMed ID: 22987732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antipsychotic agents: what do meta analyses say?].
    Millet B
    Encephale; 2007 Jun; 33 Pt 3():S419-24. PubMed ID: 19101363
    [No Abstract]   [Full Text] [Related]  

  • 13. First- vs second-generation antipsychotic drugs in schizophrenia.
    Andrade C; Kharawala S
    Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643
    [No Abstract]   [Full Text] [Related]  

  • 14. [Priority for atypical antipsychotic drugs? Current studies clarify the issues].
    Dose M
    Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological treatment of schizophrenia.
    Leucht S; Heres S; Kissling W; Davis JM
    Fortschr Neurol Psychiatr; 2013 May; 81(5):e1-13. PubMed ID: 23702802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment of adolescent and child schizophrenia.
    Young CM; Findling RL
    Expert Rev Neurother; 2004 Jan; 4(1):53-60. PubMed ID: 15853615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CUtLASS confirms CATIE.
    Mintz J; Kopelowicz A
    Arch Gen Psychiatry; 2007 Aug; 64(8):978; author reply 979-80. PubMed ID: 17679644
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunct mirtazapine for negative symptoms of schizophrenia.
    Phan SV; Kreys TJ
    Pharmacotherapy; 2011 Oct; 31(10):1017-30. PubMed ID: 21950644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.